AlphAIAlphAI — Financial news for AI agents
ir.intelliatx.comSEP 82 min read$NTLA

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics

Intellia Therapeutics (NTLA) announced FDA acceptance of its BLA for Lonvo-z, a CRISPR-based therapy for Hereditary Angioedema (HAE), with a PDUFA date of March 10, 2027. The BLA is supported by positive Phase 3 trial data showing an 87% reduction in monthly attacks. Lonvo-z aims to be the first one-time HAE treatment if approved.

Original reporting
ir.intelliatx.com
Published Sep 8, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 2:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$NTLA
Bullish
high confidence
Mentioned
$NTLA
Relevance
9/10
AlphAI data visualization · based on ir.intelliatx.com
Decision brief

The 30-second read

$NTLABullishHigh
01

Why it matters

The acceptance signals a high probability of eventual approval, which could drive significant valuation uplift for NTLA and influence peer biotech valuations.

02

Market read

Regulatory progress for a pioneering CRISPR therapy creates a notable catalyst for NTLA and may affect the broader gene‑editing sector.

03

What to watch

Potential manufacturing scale‑up challenges and competition from other HAE therapies could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Intellia's lonvo‑z is a one‑time CRISPR‑based treatment for hereditary angioedema, a rare disease with unmet needs. The BLA acceptance follows a successful Phase 3 trial.

Company-level read

Ticker impact

$NTLABullishHigh confidence
Context

Intellia Therapeutics (NASDAQ: NTLA) announced FDA acceptance of its BLA for lonvo‑z with priority review and a PDUFA target date of March 10, 2027.

Expected impact

Potential short‑to‑mid‑term price rally as investors price in the chance of a first‑in‑vivo CRISPR therapy approval.

Evidence & confidence

Regulatory acceptance is a material catalyst for biotech stocks; the priority review status and clear timeline increase market focus.

Market effects

Sector

Highlights progress in CRISPR gene‑editing therapeutics, potentially boosting sentiment for the broader biotech and gene‑therapy sector.

Regional

U.S. biotech market may see increased investor interest; limited immediate impact outside the sector.

Global

First in‑vivo CRISPR therapy could set a precedent, attracting global biotech investors.

Counterpoint

What could challenge this read

Regulatory timelines can slip; clinical data, while positive, may not translate to commercial success, warranting caution.

Key entities

  • Company
    Intellia Therapeutics

    Developer of the CRISPR‑based therapy lonvo‑z.

  • Regulator
    FDA

    U.S. Food and Drug Administration, granting priority review.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 9
$NTLAMedAI 8/10

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug

Intellia Therapeutics (NTLA) announced the FDA accepted and granted priority review to its BLA for lonvoguran ziclumeran, a CRISPR-based therapy for hereditary angioedema (HAE). A decision is expected by March 2027. The therapy showed an 87% reduction in attacks in a phase III study. NTLA shares have risen 41.7% year-to-date. The company also has another CRISPR therapy, nexiguran ziclumeran, in development with Regeneron (REGN).

tradingview.com3 min
SEP 9
$NTLAMedAI 9/10

Intellia's 'Lonvo-Z' Enters FDA Priority Review — Bids to Become World's First In Vivo CRISPR Therapy — BigGo Finance

Intellia Therapeutics' hereditary angioedema treatment, Lonvo-Z, received FDA Priority Review. If approved, it would be the first in vivo CRISPR therapy. The FDA set a PDUFA target action date of March 10, 2027. Lonvo-Z showed an 87% reduction in attacks in a Phase 3 study. Intellia's stock has risen over 35% year-to-date, with ARK Invest recently increasing its stake.

finance.biggo.com2 min
SEP 8
$NTLAHighAI 8/10

Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027

Intellia Therapeutics announced FDA acceptance of its BLA for lonvo-z, a CRISPR-based therapy, with a Priority Review and PDUFA action date of March 10, 2027. The FDA does not plan to hold an advisory committee. If approved, lonvo-z would be the first in vivo CRISPR therapy, supported by Phase 3 data showing an 87% reduction in mean monthly attacks and a 62% attack-free rate.

tradingview.com1 min
SEP 8
$NTLAHighAI 8/10

NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Revie

Intellia Therapeutics (NTLA) shares rose after the FDA granted priority review for its CRISPR-based therapy lonvo-z, targeting hereditary angioedema. The company's P/S ratio is 24.91, below its historical median, suggesting market expectations of future growth. GuruFocus' GF Value™ estimates NTLA is 4.8% undervalued at $12.63 per share, with a GF Score™ of 70/100.

gurufocus.com2 min
SEP 8
$NTLAHighAI 8/10

Why is Intellia Therapeutics stock rallying today?

Intellia Therapeutics (NTLA) stock rose 4.1% in pre-market trading after the FDA accepted its Biologics License Application for lonvoguran ziclumeran and granted Priority Review. The FDA set a target action date of March 10, 2027, and indicated no advisory committee meeting is planned. The application is based on Phase 3 trial data showing an 87% reduction in monthly HAE attacks. Citizens analysts reiterated a $30.00 price target, citing significant value in the HAE opportunity.

investing.com2 min